开发了一种三硫自由基阴离子(S 3 .− )触发的多米诺噻吩环化策略,用于合成二苯并[ d,d' ]噻吩并[2,3- b ;4,5- b ']二噻吩(DBTDT)。该多米诺骨牌协议的特点是无需金属催化剂,在一锅反应中形成六个 C−S 和一个 C−C 键。通过控制实验、中间捕获实验等提出了一种合理的机制。DBTDT独特的不对称结构赋予其人字形堆积结构和分子间弱的S⋅⋅⋅S相互作用以及高转移积分,从而实现高载流子有机场效应晶体管的迁移率为1.52 cm 2 V -1 s -1 。
Novel 3-phenylprop-2-ynylamines as inhibitors of mammalian squalene epoxidaseElectronic supplementary information (ESI) available: Proton NMR spectra for the intermediate piperidines 56–60 and acetylenes 63-81 and 85,86. See http://www.rsc.org/suppdata/ob/b2/b209165h/
作者:David L. Musso、Morris J. Clarke、James L. Kelley、G. Evan Boswell、Grace Chen
DOI:10.1039/b209165h
日期:2003.1.30
The synthesis of a novel series of 3-phenylprop-2-ynylamines as selective mammalian squalene epoxidase inhibitors is described. Structure–activity relationship studies led to the discovery of compound 19, 1-[3-(3,5-dichlorophenyl)prop-2-ynyl]-3-methylpiperidine hydrochloride with an IC50 of 2.8 ± 0.6 µM against rat liver squalene epoxidase. Against 23 strains of fungal squalene epoxidase compound 19 was found to be inactive.
One-pot synthesis of chiral alcohols from alkynes by CF<sub>3</sub>SO<sub>3</sub>H/ruthenium tandem catalysis
作者:Huan Liu、Sensheng Liu、Haifeng Zhou、Qixing Liu、Chunqin Wang
DOI:10.1039/c8ra02224k
日期:——
A practical one-pot synthesis of chiral alcohols from readily available alkynes via tandem catalysis by the combination of CF3SO3H and a fluorinated chiral diamine Ru(II) complex in aqueous CF3CH2OH is described. Very interestingly, the combination of fluorinated catalysts and solvent exhibits a positive fluorine effect on the reactivity and enantioselectivity. A range of chiral alcohols with wide
描述了通过在 CF 3 CH 2 OH水溶液中结合 CF 3 SO 3 H 和氟化手性二胺 Ru( II )配合物,从现成的炔烃通过串联催化的实用一锅法合成手性醇。非常有趣的是,氟化催化剂和溶剂的组合对反应性和对映选择性表现出积极的氟效应。在简单温和的条件下,以高收率和优异的立体选择性获得了一系列具有广泛官能团耐受性的手性醇。
[EN] TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLONE UTILISÉS COMME INHIBITEURS DE LA MPGES-1
申请人:GLENMARK PHARMACEUTICALS SA
公开号:WO2013186692A1
公开(公告)日:2013-12-19
The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.